

# Elise Siegert

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6985989/publications.pdf>

Version: 2024-02-01

32  
papers

1,019  
citations

471509

17  
h-index

501196

28  
g-index

35  
all docs

35  
docs citations

35  
times ranked

1509  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort. <i>Rheumatology</i> , 2022, 61, 4786-4796.	1.9	20
2	Systemic sclerosis-associated myositis features minimal inflammation and characteristic capillary pathology. <i>Acta Neuropathologica</i> , 2021, 141, 917-927.	7.7	19
3	Performance of ENMC and EULAR/ACR classification systems applied to a single tertiary center cohort of dermatomyositis patients. <i>Neurological Research and Practice</i> , 2021, 3, 59.	2.0	2
4	Purinergic signaling in systemic sclerosis. <i>Rheumatology</i> , 2021, , .	1.9	0
5	Scleroderma Renal Crisis: Risk Factors for an Increasingly Rare Organ Complication. <i>Journal of Rheumatology</i> , 2020, 47, 241-248.	2.0	24
6	Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. <i>Rheumatology</i> , 2020, 59, 1684-1694.	1.9	27
7	Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort. <i>Rheumatology</i> , 2020, 59, 2016-2023.	1.9	14
8	Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database. <i>Autoimmunity Reviews</i> , 2020, 19, 102452.	5.8	43
9	Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database. <i>Arthritis Research and Therapy</i> , 2020, 22, 257.	3.5	20
10	Low-dose IL-2 therapy modulates lymphocyte subsets that are involved in the regulation of germinal-centre reactions in patients with SLE. , 2020, , .		0
11	Selenium and Copper as Biomarkers for Pulmonary Arterial Hypertension in Systemic Sclerosis. <i>Nutrients</i> , 2020, 12, 1894.	4.1	23
12	Significant weight loss in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1123-1125.	0.9	11
13	Older age onset of systemic sclerosis "accelerated disease progression in all disease subsets. <i>Rheumatology</i> , 2020, 59, 3380-3389.	1.9	14
14	Response to the Letter to the Editor: Prevalence, Risk Factors and Assessment of Depressive Symptoms in Patients With Systemic Sclerosis. <i>Archives of Rheumatology</i> , 2020, 35, 460-461.	0.9	0
15	Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1576-1582.	0.9	31
16	Prevalence, Risk Factors and Assessment of Depressive Symptoms in Patients With Systemic Sclerosis. <i>Archives of Rheumatology</i> , 2019, 34, 253-261.	0.9	12
17	Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 979-987.	0.9	142
18	Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1681-1685.	0.9	13

#	ARTICLE	IF	CITATIONS
19	Does angiotensin and endothelin receptor blockade have an impact on lung function? An analysis from the EUSTAR database. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 119, 154-155.	0.8	1
20	Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 626-628.	0.9	12
21	Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group. <i>Rheumatology</i> , 2018, 57, 441-450.	1.9	60
22	Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study. <i>Arthritis and Rheumatology</i> , 2018, 70, 1829-1834.	5.6	15
23	Prevalence of sarcopenia in systemic sclerosis: assessing body composition and functional disability in patients with systemic sclerosis. <i>Nutrition</i> , 2018, 55-56, 51-55.	2.4	37
24	Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. <i>Arthritis Research and Therapy</i> , 2018, 20, 17.	3.5	75
25	Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2018, 20, 52.	3.5	44
26	Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1326-1332.	0.9	100
27	The effect of omega-3 fatty acids on central nervous system remyelination in fat-1 mice. <i>BMC Neuroscience</i> , 2017, 18, 19.	1.9	44
28	The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 270-276.	0.9	132
29	06.08â€¦Low-dose il-2 therapy in refractory sle: results from a single centre phase i/ii clinical trial. , 2017, , .		1
30	Monocytic Angiotensin and Endothelin Receptor Imbalance Modulate Secretion of the Profibrotic Chemokine Ligand 18. <i>Journal of Rheumatology</i> , 2016, 43, 587-591.	2.0	17
31	Vasoactive Therapy in Systemic Sclerosis: Real-life Therapeutic Practice in More Than 3000 Patients. <i>Journal of Rheumatology</i> , 2016, 43, 66-74.	2.0	42
32	Functional autoantibodies in systemic sclerosis. <i>Seminars in Immunopathology</i> , 2015, 37, 529-542.	6.1	23